On June 18, 2026, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), headquartered in San Carlos, California, disclosed the approval of granting inducement stock options to twenty-seven recently hired non-executive employees. The stock options cover a total of 140,860 shares of the Company's common stock. Iovance is a biotech firm specializing in creating and providing innovative polyclonal tumor infiltrating lymphocyte (“TIL”) treatments for cancer patients, demonstrating its commitment to advancing healthcare solutions.